Charles Garvin

Chairman and CEO

Mr. Garvin, a seasoned CEO and technology investor, has a BA and JD from Harvard University, and did PhD study at Oxford University as a Rhodes Scholar. Mr. Garvin served as an officer and member of the Board of Directors at the Boston Consulting Group, a leading strategy consulting organization, and was one of the original principals of the Beta Group, a seed capital firm which has incubated several successful medical technology companies. Subsequently Mr. Garvin has served as Chairman or represented controlling interests in companies including TVC Communications, Riviera Trading, EK Holdings and Basic Industries. He is currently a Director of Tosk, Inc. (cancer chemotherapies) and Senior Advisor to SanBio (stem cell therapies).

Dr. Hugh Wang

Chief Scientific Officer

Dr. Wang has an MS in Organic Chemistry from Nanjing University, followed by a PhD in Chemistry from the University of Kansas and a postdoctoral fellowship in Organic Chemistry at the University of California, Berkeley. Dr. Wang subsequently served as a Staff Scientist at Amersham Biosciences, focusing on STR (short tandem repeat) genotyping; a Senior Staff Scientist at Aclara Biosciences, focusing on high-throughput assay development using microfluidics; and co-founder of Full Moon Biosystems and Atila Biosystems, developers of antibody microarrays.

Dr. Xin Chen

Project Manager

Dr. Chen manages the detailed development of the J-probe technology and associated reagents. Dr. Chen has a PhD in Molecular Biology from the University of Texas. He subsequently served as a postdoctoral Fellow at the University of California, San Francisco, and at Stanford University, working in molecular neurogenetics.